

1 **Treatment information of the other-regimens group**

2 In the other-regimens group, 6 patients received triptergium wilfordii (TW) (60 – 120 mg/d)
3 for 6 month as induction therapy, 2 received MMF (0.5 – 1.0 g/d) and tacrolimus (2 mg/d) for 6
4 months, and 3 received CYC (0.5 – 0.75 g/m² body surface area) for 3 months followed by TW (60
5 – 120 mg/d). All patients received three methylprednisolone injections of 500 mg per day for 3
6 days followed by oral corticosteroids at doses of 0.6 – 0.8 mg per kilogram of body weight per day.
7 Maintenance therapy was started at the end of induction therapy with low doses prednisone and
8 immunosuppressors, including azathioprine, leflunomide, and TW.

9 **Outcomes of the other-regimens group**

10 During follow-up (median: 81.60 [IQR, 34.90 – 119.90] months), no patient had ESRD.

Supplementary Table 1 Baseline characteristics of ANCA-positive LN patients based on induction therapies

	Total (N = 49)	MMF group (n = 20)	CYC group (n = 18)	The other-regimens group (n = 11)	P-value*
<i>Clinical data at biopsy</i>					
Men	9 (18.37)	3 (15.00)	5 (27.78)	1 (9.09)	0.438
Age, yrs	33 (26 - 40)	33 (25 - 42)	28 (24 - 35)	34 (30 - 39)	0.558
Body mass index, kg/m ²	20.68 (19.44 – 23.07)	20.20 (19.25 – 22.00)	23.45 (21.44 – 26.23)	20.59 (19.29 – 21.92)	0.063
Smoker	1 (2.04)	1 (5.00)	0 (0.00)	0 (0.00)	0.900
Atherosclerosis	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0.900
Diabetes	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0.900
SLEDAI, score	14 (12 – 18)	16 (14 -19)	15 (13 - 21)	12 (11 - 16)	0.638
Proteinuria, g/24 h	2.81 (1.11 – 5.04)	2.78 (1.65 – 4.98)	3.71 (2.16 – 7.30)	3.59 (1.16 – 5.05)	0.148
Urinary RBC count, ×10 ⁴ /mL	101 (25 - 525)	171 (54 - 746)	135 (30 - 338)	42 (3 - 101)	0.388
SAlb, g/L	27.40 (21.55 – 32.65)	28.90 (24.33 – 34.70)	25.8 (18.83 – 30.03)	28.00 (24.90 – 31.10)	0.063
SCr, μmol/L	91.05 (74.26 – 147.63)	101.67 (73.15 – 133.71)	86.63 (76.02 – 152.05)	76.91 (48.62 – 154.70)	0.826

MPO-ANCA positivity	39 (79.59)	15 (75.00)	16 (88.89)	8 (72.73)	0.410
<i>Pathological findings at biopsy</i>					
Pathological classification					
Class III/ III+V	11 (22.45)	5 (25.00)	3 (16.67)	3 (27.27)	0.697
Class IV/ IV+V	34 (69.39)	15 (75.00)	13 (72.22)	6 (54.55)	0.900
Class V	3 (6.12)	0 (0.00)	1 (5.56)	2 (18.18)	0.474
AI, score	8.31 ± 4.36	9.45 ± 4.42	7.89 ± 4.50	5.55 ± 3.78	0.284
CI, score	2.92 ± 2.23	2.75 ± 2.25	3.39 ± 2.30	1.91 ± 2.17	0.314
Cellular crescents, score	1.31 ± 1.03	1.75 ± 0.85	0.89 ± 0.96	0.82 ± 0.87	0.007
Fibrous crescents, score	0.22 ± 0.42	0.25 ± 0.44	0.33 ± 0.49	0.00 ± 0.00	0.577
<i>Double-filtration plasmapheresis/Plasma exchange</i>					
	1 (2.04)	1 (5.00)	0 (0.00)	0 (0.00)	0.900
<i>Maintenance therapy</i>					
Azathioprine	7 (14.29)	2 (10.00)	3 (16.67)	2 (18.18)	0.653
Leflunomide	5 (10.20)	1 (5.00)	3 (16.67)	1 (9.09)	0.328

Hydroxychloroquine	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0.900
Triptergium wilfordii	28 (57.14)	15 (75.00)	9 (50.00)	4 (36.36)	0.179

* Comparison of MMF with CYC in the treatment of ANCA-positive LN patients

Values are given as n (%) or median (interquartile range) or mean \pm standard deviation.

ANCA, antineutrophil cytoplasmic antibody; LN, lupus nephritis; MMF, mycophenolate mofetil; CYC, cyclophosphamide; SLEDAI, systemic lupus erythematosus disease activity index; RBC, red blood cell; SALb, serum albumin; SCr, serum creatinine; MPO-ANCA, myeloperoxidase antineutrophil cytoplasmic antibody; AI, activity index; CI, chronicity index.